Skip to content
OpenCapital
Get started

United Therapeutics UTHR Nebulized Tyvaso — Cost of Sales

Other product segments

Tyvaso DPI
$83.2M+73.0%
Remodulin
$16.1M+16.7%
Orenitram
$7.4M-10.8%
Unituxin
$5M-3.8%
Adcirca
$1M-61.5%

Similar metrics at other companies

Mannkind logo
MNKDCollaborations And Services Related To Tyvaso DPI — Cost Of Revenue
$10M-27.0%
Mannkind logo
MNKDTyvaso DPI — Percentage Of Royalty On Net Sales
10%0.0pp
Mannkind logo
MNKDTyvaso DPI — Percentage Of Royalty On Net Revenue
10%0.0pp
Ardelyx logo
ARDXProduct sales, net — Cost of Sales
$2.88M+22.9%
Travere Therapeutics, Inc. logo
TVTXTotal net product sales — Cost of goods sold
$1.95M+55.6%
Mirum Pharmaceuticals, Inc. logo
MIRMCost of Sales
$28.81M+25.1%

Other financials

Income statement

See full
Revenue$781.5M-1.6%
Gross profit$648.1M-7.7%
Operating income$325.8M-14.9%
Net income$274.9M-14.7%
EPS (diluted)$5.82-12.2%

Balance sheet

See full
Cash & equivalents$1.3B-32.6%
Total debt$12.2M—
Total equity$5.9B-13.3%
Total assets$6.7B-13.3%

Cash flow

See full
Operating cash flow$463.3M+0.5%
CapEx$100.8M+34.6%
Free cash flow$362.5M-6.2%

Valuation

See full
Market cap$23B+84.1%
P/E17.9×+7.8×
P/S7.3×+3.2×

Profitability

See full
Gross margin86.6%-2.4pp
Operating margin45.3%-1.6pp
Net margin40.6%+0.2pp
FCF margin32.1%-5.6pp

Returns & leverage

See full
Return on equity20.3%+0.3pp
Debt / equity0×—
Current ratio4.8×-0.7×

Where this comes from

Reported directly by United Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.

The official record: United Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about United Therapeutics's nebulized tyvaso — cost of sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is United Therapeutics's nebulized tyvaso — cost of sales?
United Therapeutics (UTHR) reported nebulized tyvaso — cost of sales of $8.6M in Q1 2026.
How has United Therapeutics's nebulized tyvaso — cost of sales changed year-over-year?
United Therapeutics's nebulized tyvaso — cost of sales increased by 1.2% year-over-year, from $8.5M to $8.6M.
What is the long-term trend for United Therapeutics's nebulized tyvaso — cost of sales?
Over 3 years (2021 to 2025), United Therapeutics's nebulized tyvaso — cost of sales has grown at a 0.5% compound annual growth rate (CAGR), from $26.8M to $27.2M.
What does nebulized tyvaso — cost of sales mean?
This metric captures the direct costs associated with manufacturing, packaging, and distributing the nebulized drug product. It includes raw material expenses, production labor, and logistics costs required to bring the specific therapy to market. Monitoring this figure allows for the evaluation of production efficiency and the impact of supply chain management on the product's unit economics.